261 related articles for article (PubMed ID: 11001329)
41. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.
Honeyman L; Ismail M; Nelson ML; Bhatia B; Bowser TE; Chen J; Mechiche R; Ohemeng K; Verma AK; Cannon EP; Macone A; Tanaka SK; Levy S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7044-53. PubMed ID: 26349824
[TBL] [Abstract][Full Text] [Related]
42. In vitro activities of two glycylcyclines against gram-positive bacteria.
Eliopoulos GM; Wennersten CB; Cole G; Moellering RC
Antimicrob Agents Chemother; 1994 Mar; 38(3):534-41. PubMed ID: 8203851
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.
Petersen PJ; Bradford PA; Weiss WJ; Murphy TM; Sum PE; Projan SJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2595-601. PubMed ID: 12121938
[TBL] [Abstract][Full Text] [Related]
44. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics.
Rossi F; García P; Ronzon B; Curcio D; Dowzicky MJ
Braz J Infect Dis; 2008 Oct; 12(5):405-15. PubMed ID: 19219281
[TBL] [Abstract][Full Text] [Related]
45. Tigecycline for the treatment of infections due to resistant Gram-positive organisms.
Squires RA; Postier RG
Expert Opin Investig Drugs; 2006 Feb; 15(2):155-62. PubMed ID: 16433594
[TBL] [Abstract][Full Text] [Related]
46. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
[TBL] [Abstract][Full Text] [Related]
47. [In vitro activity of tigecycline against methicillin-resistant staphylococci].
Tunçkanat F; Saribaş Z; Ercis S
Mikrobiyol Bul; 2009 Apr; 43(2):211-5. PubMed ID: 19621605
[TBL] [Abstract][Full Text] [Related]
48. Tigecycline is modified by the flavin-dependent monooxygenase TetX.
Moore IF; Hughes DW; Wright GD
Biochemistry; 2005 Sep; 44(35):11829-35. PubMed ID: 16128584
[TBL] [Abstract][Full Text] [Related]
49. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
Balode A; Punda-Polić V; Dowzicky MJ
Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
[TBL] [Abstract][Full Text] [Related]
50. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
[TBL] [Abstract][Full Text] [Related]
51. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.
Monogue ML; Thabit AK; Hamada Y; Nicolau DP
Antimicrob Agents Chemother; 2016 Aug; 60(8):5001-5. PubMed ID: 27353265
[TBL] [Abstract][Full Text] [Related]
52. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.
Jones CH; Petersen PJ
Drugs Today (Barc); 2005 Oct; 41(10):637-59. PubMed ID: 16389407
[TBL] [Abstract][Full Text] [Related]
53. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
54. Tigecycline: clinical evidence and formulary positioning.
Nathwani D
Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
[TBL] [Abstract][Full Text] [Related]
55. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
Nannini EC; Pai SR; Singh KV; Murray BE
Antimicrob Agents Chemother; 2003 Feb; 47(2):529-32. PubMed ID: 12543654
[TBL] [Abstract][Full Text] [Related]
56. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).
Hirata T; Saito A; Nishino K; Tamura N; Yamaguchi A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2179-84. PubMed ID: 15155219
[TBL] [Abstract][Full Text] [Related]
57. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
58. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.
Goldstein FW; Kitzis MD; Acar JF
Antimicrob Agents Chemother; 1994 Sep; 38(9):2218-20. PubMed ID: 7811053
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
60. [Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain].
García-Rodríguez JA;
Rev Esp Quimioter; 2009 Jun; 22(2):76-82. PubMed ID: 19554486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
